Inibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativa
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Tipo de documento: | Trabalho de conclusão de curso |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFS |
Texto Completo: | https://ri.ufs.br/handle/riufs/6791 |
Resumo: | Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm of hematopoietic stem cells characterized by excessive accumulation of myeloid cells. Previously the treatment of the disease was based only on chemotherapy and allogeneic transplantation. Today the treatment is based on the 1st, 2nd and 3rd generation tyrosine kinase inhibitors Material and Methods: A narrative review was performed in the Lilacs, Scielo and Pubmed databases using the terms: ("CML") ("tyrosine kinase inhibitors ") And (" treatment "). Results: Of the articles found in more than one database, 18 articles were analyzed and read in their entirety. Of which 8 were carried out in Brazil, 6 in the United States and only one in Germany, Italy, Japan and Taiwan respectively, publications are in the period from 2009 to 2015. 44.44% (8) are articles of revision and 55.56% (10) were original articles. Review articles were excluded from this research. Regarding the drugs studied, 50% (5) had as study focus the drug Imatinib; 30% (3) compared the drugs Imatinib, Dasatinib and Nilotinib in relation to the therapeutic response; 10% (1) also evaluated the therapeutic response of Imatinib, Busutinib and Ponatinib; and 10% (1) of the studies evaluated only Dasatinib. Conclusion: Second- and third-generation tyrosine kinase inhibitors, when compared in the literature to the first generation drug (Imatinib), present a faster therapeutic response, greater survival and a better quality of life. |
id |
UFS-2_13227cc13a0fe7e50a849b5a3e78f312 |
---|---|
oai_identifier_str |
oai:ufs.br:riufs/6791 |
network_acronym_str |
UFS-2 |
network_name_str |
Repositório Institucional da UFS |
repository_id_str |
|
spelling |
Vieira, Paulina CoutinhoSilva, Wellington Barros da2017-10-30T13:40:11Z2017-10-30T13:40:11Z2016-05-18VIEIRA, Paulina Coutinho. Inibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativa. 2016. Monografia (Bacharel em Farmácia) - Departamento de Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Sergipe, São Cristóvão, SE, 2016https://ri.ufs.br/handle/riufs/6791Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm of hematopoietic stem cells characterized by excessive accumulation of myeloid cells. Previously the treatment of the disease was based only on chemotherapy and allogeneic transplantation. Today the treatment is based on the 1st, 2nd and 3rd generation tyrosine kinase inhibitors Material and Methods: A narrative review was performed in the Lilacs, Scielo and Pubmed databases using the terms: ("CML") ("tyrosine kinase inhibitors ") And (" treatment "). Results: Of the articles found in more than one database, 18 articles were analyzed and read in their entirety. Of which 8 were carried out in Brazil, 6 in the United States and only one in Germany, Italy, Japan and Taiwan respectively, publications are in the period from 2009 to 2015. 44.44% (8) are articles of revision and 55.56% (10) were original articles. Review articles were excluded from this research. Regarding the drugs studied, 50% (5) had as study focus the drug Imatinib; 30% (3) compared the drugs Imatinib, Dasatinib and Nilotinib in relation to the therapeutic response; 10% (1) also evaluated the therapeutic response of Imatinib, Busutinib and Ponatinib; and 10% (1) of the studies evaluated only Dasatinib. Conclusion: Second- and third-generation tyrosine kinase inhibitors, when compared in the literature to the first generation drug (Imatinib), present a faster therapeutic response, greater survival and a better quality of life.Introdução: A leucemia mieloide crônica (LMC) é uma neoplasia mieloproliferativa de células-tronco hematopoiéticas caracterizada pelo acúmulo excessivo de células mielóides. Anteriormente o tratamento da doença era baseado apenas em quimioterapia e no transplante alogênico. Hoje o tratamento é baseado nos inibidores da tirosina quinase de 1º, 2º e 3º geração Material e Métodos: Foi realizada uma revisão narrativa nas bases de dados Lilacs, Scielo e Pubmed utilizando os termos: (“LMC”) (“inibidores da tirosina quinase”) and (“tratamento”). Resultados: Dos artigos encontrados em mais de uma base de dados, 18 artigos foram analisados e lidos na íntegra. Dos quais 8 foram realizados no Brasil, 6 nos Estados Unidos e apenas um realizado na Alemanha, Itália, Japão e Taiwan respectivamente, as publicações situam-se no período do ano de 2009 a 2015. 44,44% (8) são artigos de revisão e 55,56% (10) eram artigos originais. Os artigos de revisão foram excluídos dessa pesquisa. Em relação aos fármacos estudados, 50% (5) tiveram como foco de estudo o fármaco Imatinib; 30% (3) estudaram comparativamente os fármacos Imatinib, Dasatinib e Nilotinib em relação à resposta terapêutica, 10% (1) também avaliaram a resposta terapêutica dos medicamentos Imatinib, Busutinib e Ponatinib; e 10% (1) dos estudos avaliaram apenas o fármaco Dasatinib. Conclusão: Os inibidores da segunda e terceira geração da tirosina quinase quando comparados na literatura ao fármaco de primeira geração (Imatinib), apresentam uma resposta terapêutica mais rápida, maior sobrevida e uma melhor qualidade de vida.São Cristóvão, SEporFarmáciaDrugstoreEnsino de famacologiaTeaching of famacologyLeucemiaTratamento de leucemiaCIENCIAS BIOLOGICAS::FARMACOLOGIA::FARMACOLOGIA GERALInibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativaInhibitors of Tirosine Kinase in the treatment of CML: a narrative reviewinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/bachelorThesisUniversidade Federal de SergipeDFA - Departamento de Farmácia – São Cristóvão - Presencialreponame:Repositório Institucional da UFSinstname:Universidade Federal de Sergipe (UFS)instacron:UFSinfo:eu-repo/semantics/openAccessLICENSElicense.txtlicense.txttext/plain; charset=utf-81475https://ri.ufs.br/jspui/bitstream/riufs/6791/1/license.txt098cbbf65c2c15e1fb2e49c5d306a44cMD51ORIGINALPaulina Coutinho Vieira.pdfPaulina Coutinho Vieira.pdfapplication/pdf377980https://ri.ufs.br/jspui/bitstream/riufs/6791/2/Paulina%20Coutinho%20Vieira.pdf57d967a62bed6ce54a7120aa3758f728MD52TEXTPaulina Coutinho Vieira.pdf.txtPaulina Coutinho Vieira.pdf.txtExtracted texttext/plain40218https://ri.ufs.br/jspui/bitstream/riufs/6791/3/Paulina%20Coutinho%20Vieira.pdf.txt0f8264c1eb6d9dd90f5abe2031bc78d8MD53THUMBNAILPaulina Coutinho Vieira.pdf.jpgPaulina Coutinho Vieira.pdf.jpgGenerated Thumbnailimage/jpeg1326https://ri.ufs.br/jspui/bitstream/riufs/6791/4/Paulina%20Coutinho%20Vieira.pdf.jpg3f1e9ff796a092fc80a18db081b64a9fMD54riufs/67912017-11-01 20:46:18.923oai:ufs.br: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Repositório InstitucionalPUBhttps://ri.ufs.br/oai/requestrepositorio@academico.ufs.bropendoar:2017-11-01T23:46:18Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS)false |
dc.title.pt_BR.fl_str_mv |
Inibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativa |
dc.title.alternative.eng.fl_str_mv |
Inhibitors of Tirosine Kinase in the treatment of CML: a narrative review |
title |
Inibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativa |
spellingShingle |
Inibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativa Vieira, Paulina Coutinho Farmácia Drugstore Ensino de famacologia Teaching of famacology Leucemia Tratamento de leucemia CIENCIAS BIOLOGICAS::FARMACOLOGIA::FARMACOLOGIA GERAL |
title_short |
Inibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativa |
title_full |
Inibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativa |
title_fullStr |
Inibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativa |
title_full_unstemmed |
Inibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativa |
title_sort |
Inibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativa |
author |
Vieira, Paulina Coutinho |
author_facet |
Vieira, Paulina Coutinho |
author_role |
author |
dc.contributor.author.fl_str_mv |
Vieira, Paulina Coutinho |
dc.contributor.advisor1.fl_str_mv |
Silva, Wellington Barros da |
contributor_str_mv |
Silva, Wellington Barros da |
dc.subject.por.fl_str_mv |
Farmácia Drugstore Ensino de famacologia Teaching of famacology Leucemia Tratamento de leucemia |
topic |
Farmácia Drugstore Ensino de famacologia Teaching of famacology Leucemia Tratamento de leucemia CIENCIAS BIOLOGICAS::FARMACOLOGIA::FARMACOLOGIA GERAL |
dc.subject.cnpq.fl_str_mv |
CIENCIAS BIOLOGICAS::FARMACOLOGIA::FARMACOLOGIA GERAL |
description |
Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm of hematopoietic stem cells characterized by excessive accumulation of myeloid cells. Previously the treatment of the disease was based only on chemotherapy and allogeneic transplantation. Today the treatment is based on the 1st, 2nd and 3rd generation tyrosine kinase inhibitors Material and Methods: A narrative review was performed in the Lilacs, Scielo and Pubmed databases using the terms: ("CML") ("tyrosine kinase inhibitors ") And (" treatment "). Results: Of the articles found in more than one database, 18 articles were analyzed and read in their entirety. Of which 8 were carried out in Brazil, 6 in the United States and only one in Germany, Italy, Japan and Taiwan respectively, publications are in the period from 2009 to 2015. 44.44% (8) are articles of revision and 55.56% (10) were original articles. Review articles were excluded from this research. Regarding the drugs studied, 50% (5) had as study focus the drug Imatinib; 30% (3) compared the drugs Imatinib, Dasatinib and Nilotinib in relation to the therapeutic response; 10% (1) also evaluated the therapeutic response of Imatinib, Busutinib and Ponatinib; and 10% (1) of the studies evaluated only Dasatinib. Conclusion: Second- and third-generation tyrosine kinase inhibitors, when compared in the literature to the first generation drug (Imatinib), present a faster therapeutic response, greater survival and a better quality of life. |
publishDate |
2016 |
dc.date.issued.fl_str_mv |
2016-05-18 |
dc.date.accessioned.fl_str_mv |
2017-10-30T13:40:11Z |
dc.date.available.fl_str_mv |
2017-10-30T13:40:11Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
format |
bachelorThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
VIEIRA, Paulina Coutinho. Inibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativa. 2016. Monografia (Bacharel em Farmácia) - Departamento de Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Sergipe, São Cristóvão, SE, 2016 |
dc.identifier.uri.fl_str_mv |
https://ri.ufs.br/handle/riufs/6791 |
identifier_str_mv |
VIEIRA, Paulina Coutinho. Inibidores da Tirosina Quinase no tratamento da LMC : uma revisão narrativa. 2016. Monografia (Bacharel em Farmácia) - Departamento de Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Sergipe, São Cristóvão, SE, 2016 |
url |
https://ri.ufs.br/handle/riufs/6791 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.initials.fl_str_mv |
Universidade Federal de Sergipe |
dc.publisher.department.fl_str_mv |
DFA - Departamento de Farmácia – São Cristóvão - Presencial |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFS instname:Universidade Federal de Sergipe (UFS) instacron:UFS |
instname_str |
Universidade Federal de Sergipe (UFS) |
instacron_str |
UFS |
institution |
UFS |
reponame_str |
Repositório Institucional da UFS |
collection |
Repositório Institucional da UFS |
bitstream.url.fl_str_mv |
https://ri.ufs.br/jspui/bitstream/riufs/6791/1/license.txt https://ri.ufs.br/jspui/bitstream/riufs/6791/2/Paulina%20Coutinho%20Vieira.pdf https://ri.ufs.br/jspui/bitstream/riufs/6791/3/Paulina%20Coutinho%20Vieira.pdf.txt https://ri.ufs.br/jspui/bitstream/riufs/6791/4/Paulina%20Coutinho%20Vieira.pdf.jpg |
bitstream.checksum.fl_str_mv |
098cbbf65c2c15e1fb2e49c5d306a44c 57d967a62bed6ce54a7120aa3758f728 0f8264c1eb6d9dd90f5abe2031bc78d8 3f1e9ff796a092fc80a18db081b64a9f |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFS - Universidade Federal de Sergipe (UFS) |
repository.mail.fl_str_mv |
repositorio@academico.ufs.br |
_version_ |
1802110644172881920 |